Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGAV | P06756 | 4/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 9/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250421 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVPPARGTLR8 | |
| SCHEMBL8043860 | 0.87 | ITGB3 (0.52) | ITGB3ITGAVPPARGTLR8 | |
| SCHEMBL8044747 | 0.84 | ITGB3 (0.75) | ITGB3ITGAVEGLN1 | |
| SCHEMBL8047408 | 0.81 | ITGB3 (0.53) | ITGB3ITGAVTLR8 | |
| SCHEMBL8042427 | 0.81 | ITGB3 (0.43) | ITGB3ITGAV | |
| SCHEMBL8042836 | 0.80 | ITGB3 (0.56) | ITGB3ITGAVPPARGTLR8 | |
| SCHEMBL8033019 | 0.77 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL8050869 | 0.76 | ITGB3 (0.46) | ITGB3ITGAVEGLN1 | |
| SCHEMBL8032428 | 0.76 | ITGB3 (0.48) | ITGB3ITGAVTLR8 | |
| SCHEMBL30963677 | 0.76 | ITGB3 (0.47) | ITGB3ITGAVEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2007001249-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | MSR1, EDNRA, GPR174 | ITGB3 28/4885ITGAV 133/4885EGLN1 1407/4885 |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | ITGB3 672/4885ITGAV 1292/4885EGLN1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.